Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
ceftazidime pentahydrate, Quantity: 2.328 g (Equivalent: ceftazidime, Qty 2 g)
Juno Pharmaceuticals Pty Ltd
ceftazidime pentahydrate
Injection, powder for
Excipient Ingredients: sodium carbonate
Intravenous
Single Pack
(S4) Prescription Only Medicine
CEFTAZIDIME JUNO is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antibiotics cannot be used. Indications include: Severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. Respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. Severe ear, nose and throat infections: for example: otitis media, mastoiditis. Urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. Skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. Gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. Bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.
Visual Identification: White or cream coloured powder supplied in 50 mL capacity colourless, Type III glass vials, and sealed with Helvoet Pharma FM257/2 dark grey bromobutyl rubber stopper and dark green aluminium flip-off cap.; Container Type: Vial; Container Material: Glass Type III Clear; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2006-09-19
Page 1 CEFTAZIDIME JUNO Ceftazidime (as pentahydrate) (ke-TAZ-e-deem _)_ _ _ _ _ CONSUMER MEDICINE INFORMATION _Date of Dispensing _ _Consumer Name _ _Pharmacist Name_ _Consumer Address _ _Pharmacist Address_ _ _ _ _ WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Ceftazidime Juno. It does not contain all the available information. It does not take the place of talking to your doctor and pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you being given Ceftazidime Juno against the benefits this medicine is expected to have for you. IF YOU HAVE ANY CONCERNS ABOUT BEING GIVEN THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET IN A SAFE PLACE. You may need to read it again. WHAT CEFTAZIDIME JUNO IS USED FOR Ceftazidime is an antibiotic used to treat infections in different parts of the body caused by bacteria. Ceftazidime will not work against infections caused by viruses such as colds or the flu. Ceftazidime belongs to a group of antibiotics called cephalosporins (cef-a-loe-SPOR-ins). These antibiotics work by killing the bacteria that are causing your infection. Your doctor may have prescribed ceftazidime for another reason ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY CEFTAZIDIME HAS BEEN PRESCRIBED FOR YOU. This medicine is available only with a doctor’s prescription. BEFORE YOU ARE GIVEN CEFTAZIDIME JUNO _WHEN YOU MUST NOT BE _ _GIVEN IT_ _ _ CEFTAZIDIME JUNO IF YOU HAVE AN ALLERGY TO: • ceftazidime • other cephalosporins • any of the ingredients listed at the end of this leaflet. • lignocaine Some of the symptoms of an allergic reaction may include: • shortness of breath, wheezing or difficulty breathing; • swelling of the face, lips, tongue or other parts of the body; • rash, itching or hives on the skin. YOU MUST NOT BE GIVEN THIS MEDICINE IF YOU HAVE HAD A SERIOUS ALLERGIC REACTION TO PENICILLIN ANTIBIOTICS. CEFTAZIDIME SHOULD NOT BE MIXED WITH LIGNOCAINE AND GIVEN TO YOU IF YOU HAVE HAD AN ALLERGIC REACTION TO Read the complete document
Juno Pharmaceuticals Pty Ltd Australian Product Information Page | 1 AUSTRALIAN PRODUCT INFORMATION CEFTAZIDIME JUNO _(CEFTAZIDIME (AS PENTAHYDRATE)) _ _ _ 1 NAME OF THE MEDICINE Ceftazidime (as pentahydrate) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Ceftazidime Juno powder for injection is a cephalosporin antibiotic for use by injection only. Ceftazidime pentahydrate is slightly soluble in water and in methanol, practically insoluble in acetone and in ethanol. It dissolves in acid and alkali solutions. Ceftazidime Juno is in vials containing 1 g and 2 g ceftazidime (as pentahydrate). For the full list of excipients, see Section 6.1 List of excipients. For laboratory tests associated with ceftazidime administration, ceftazidime pentahydrate should be used. 3 PHARMACEUTICAL FORM Ceftazidime Juno is a powder for injection and is a white or cream coloured powder. On the addition of water for injections, Ceftazidime Juno powder for injection dissolves with effervescence to produce a clear, colourless solution for injection. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ceftazidime Juno powder for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. Indications include: • Severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. • Respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. • Severe ear, nose and throat infections: for example, otitis media, mastoiditis. • Urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial onl Read the complete document